Health TrialsbyHealthPanel

Diagnosing Frontotemporal Lobar Degeneration

ConditionsCorticobasal SyndromeProgressive Supranuclear PalsyBehavioral Variant Frontotemporal DementiaSemantic DementiaProgressive Nonfluent AphasiaAmyotrophic Lateral Sclerosis And/or Frontotemporal Dementia
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-90
SponsorUniversity Health Network, Toronto

About this trial

To establish diagnostic tools to make an accurate clinical and pathological diagnosis of patients with clinical FTLD syndromes

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Participant must have a reliable study partner who can provide an independent evaluation of functioning.

Able to read, understand and speak English for neuropsychological testing.

All subjects must meet one of these diagnostic criteria (A) probable behavioral variant FTD, (B) MRI-supported non-fluent variant PPA; (C) MRI-supported semantic variant PPA and [18F]T807 negative (D) probable CBS: using current criteria for CBS(27); (E) PSP: inclusion criteria for PSP are based upon the National Institute of Neurological Disorders and Stroke Society of Progressive Supranuclear Palsy (NINDS-SPSP) (F) FTD-MND

Control subjects must have a normal neurological exam, a CDR sum of boxes = 0, and MMSE score equal to or greater than 28

Disqualifiers

Patients with clinical, imaging or CSF A beta/ tau profile consistent with AD

History of traumatic brain injury, brain tumors, stroke or other neurological or psychiatric disorders that can explain symptoms will be excluded.

Premenopausal women will be asked to consent to a pregnancy test prior to each scan as pregnant women will be excluded from study because of potential harm to fetus from PET study.

Presence of pacemakers, aneurysm clips, artificial heart valves, ear implants, metal fragments or foreign objects in the eyes, skin or body.

Trial population

Patients with a diagnosis of progressive supranuclear palsy (PSP), corticobasal syndrome (CBS), semantic variant primary progressive aphasia (sv-PPA), non-fluent variant PPA (nfv-PPA), behavioral variant frontotemporal dementia (bvFTD) or FTD-motor neuron disease (FTD-MND).

Trial design

Design model

Cohort

Time perspective

Cross-sectional

Treatments tested in this trial

  • Observational Study

    Other intervention

Treatment groups

100 Participants
are divided into 7 treatment groups

7

Treatment groups

See each treatment group below.

Group A: Progressive supranuclear palsy1 intervention
Group B: Corticobasal syndrome1 intervention
Group C: Behavoral variant FTD1 intervention
Group D: Semantic variant PPA1 intervention
Group E: Non-fluent variant PPA1 intervention
Group F: FTD-motor neuron disease1 intervention
Group G: Healthy controls1 intervention

Trial outcomes

Primary outcomes

1

Structural and Functional Diffferences between the FTLD groups via MRI of the brain

Differences in brain volumes and resting state functional connectivity

Time frame
One time visit through study completion of 5 years
2

Differences between the FTLD groups via PET imaging of the brain

Differences in ligand uptake

Time frame
One time visit through study completion of 5 years

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Health Network, Toronto

Lead sponsor

Source ClinicalTrials.gov
Apply now